Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long-term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group.

Rammeloo LA, Postma A, Sobotka-Plojhar MA, Bink-Boelkens MT, Berg A, Veerman AJ, Kamps WA.

Med Pediatr Oncol. 2000 Jul;35(1):13-9.

PMID:
10881002
2.

Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.

Bryant J, Picot J, Levitt G, Sullivan I, Baxter L, Clegg A.

Health Technol Assess. 2007 Jul;11(27):iii, ix-x, 1-84. Review.

3.

Exposure to anthracyclines during childhood causes cardiac injury.

Lipshultz SE.

Semin Oncol. 2006 Jun;33(3 Suppl 8):S8-14. Review.

PMID:
16781284
5.

Role of anthracyclines in the treatment of adult acute lymphoblastic leukemia.

Bassan R, Lerede T, Rambaldi A, Barbui T.

Acta Haematol. 1996;95(3-4):188-92. Review.

PMID:
8677741
6.

Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health.

Ness KK, Armenian SH, Kadan-Lottick N, Gurney JG.

Expert Rev Hematol. 2011 Apr;4(2):185-97. doi: 10.1586/ehm.11.8. Review.

Supplemental Content

Support Center